Detection of Wilms' Tumor Antigen–Specific CTL in Tumor-Draining Lymph Nodes of Patients with Early Breast Cancer
Open Access
- 1 January 2006
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 12 (1), 34-42
- https://doi.org/10.1158/1078-0432.ccr-05-1483
Abstract
Purpose: The Wilms' tumor antigen (WT1) is overexpressed in ∼90% of breast tumors and, thus, is a potential target antigen for the immunotherapy of breast cancer. We have tested the working hypotheses that WT1 can be immunogenic in patients with breast cancer and can stimulate CTL of sufficient avidity to kill tumor cells.Keywords
This publication has 33 references indexed in Scilit:
- WT1 is a tumor‐associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cellsInternational Journal of Cancer, 2004
- Cancer Statistics, 2004CA: A Cancer Journal for Clinicians, 2004
- Complete remission in a patient with recurrent acute myeloid leukemia induced by vaccination with WT1 peptide in the absence of hematological or renal toxicityLeukemia, 2003
- Functional leukemia-associated antigen-specific memory CD8+ T cells exist in healthy individuals and in patients with chronic myelogenous leukemia before and after stem cell transplantationBlood, 2003
- CD8 T-cell responses to Wilms tumor gene product WT1 and proteinase 3 in patients with acute myeloid leukemiaBlood, 2002
- Escaping High Viral Load ExhaustionThe Journal of Experimental Medicine, 2002
- Eradication of adenovirus E1-induced tumors by E1A-specific cytotoxic T lymphocytesCell, 1989
- Studies of the HER-2/ neu Proto-Oncogene in Human Breast and Ovarian CancerScience, 1989
- Human Breast Cancer: Correlation of Relapse and Survival with Amplification of the HER-2/ neu OncogeneScience, 1987
- Homozygous deletions that simultaneously eliminate expressions of class I and class II antigens of EBV-transformed B-lymphoblastoid cells. I. Reduced proliferative responses of autologous and allogeneic T cells to mutant cells that have decreased expression of class II antigensHuman Immunology, 1984